BTIG Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $112
Portfolio Pulse from Benzinga Newsdesk
BTIG has initiated coverage on Haemonetics with a Buy rating and set a price target of $112, indicating a positive outlook for the company's stock.
September 10, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Marie Thibault has initiated coverage on Haemonetics with a Buy rating and a price target of $112, suggesting a positive short-term outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $112 by BTIG suggests confidence in Haemonetics' future performance. This is likely to positively influence investor sentiment and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100